Similar Search Results

Network Effects and Diffusion in Pharmaceutical Markets : Antiulcer Drugs

Berndt, Ernst R. - 1999

We examine the role of network effects in the demand for pharmaceuticals at both the brand level and for a therapeutic …

Persistent link: https://www.econbiz.de/10012471776

European Pharmaceutical Price Regulation, Firm Profitability, and R&D Spending

Golec, Joseph H. - 2006

EU countries closely regulate pharmaceutical prices whereas the U.S. does not. This paper shows how price constraints affect the profitability, stock returns, and R&D spending of EU and U.S. firms. Compared to EU firms, U.S. firms are more profitable, earn higher stock returns, and spend more on...

Persistent link: https://www.econbiz.de/10012465985

Evaluating Pharmaceutical Policy Options

Ho, Katherine; Pakes, Ariel - National Bureau of Economic Research - 2024

Our calculations indicate that currently proposed U.S. policies to reduce pharmaceutical prices, though particularly beneficial for low-income and elderly populations, could dramatically reduce firms' investment in highly welfare-improving R&D. The U.S. subsidizes the worldwide pharmaceutical...

Persistent link: https://www.econbiz.de/10014576635

Generics and New Goods in Pharmaceutical Price Indexes

Griliches, Zvi - 1993

We examine the issue of new goods and price indexes for the important and tractable case of generic and branded drugs. By treating generics as entirely distinct goods and "linking them in" to indexes with fixed weights, the standard price indexes fail to reflect the substantial welfare gains to...

Persistent link: https://www.econbiz.de/10012474690

Improving Regulation for Innovation : Evidence from China's Pharmaceutical Industry

Jia, Ruixue; Ma, Xiao; Yang, Jianan; Zhang, Yiran - National Bureau of Economic Research - 2023

This study investigates how enhanced regulation can promote innovation, focusing on the impacts of a significant … recognized the improvement in drug innovation, as reflected in stock price adjustments post new drug registrations after the … latecomers could boost their innovation potential by adopting specific, effective regulatory practices from frontier countries …

Persistent link: https://www.econbiz.de/10014447297

Consumption Externalities and Diffusion in Pharmaceutical Markets : Antiulcer Drugs

Berndt, Ernst R. - 2000

We examine the role of consumption externalities in the demand for pharmaceuticals at both the brand level and over a …

Persistent link: https://www.econbiz.de/10012470978

Pharmacy Benefit Managers and Vertical Relationships in Drug Supply : State of Current Research

Brot-Goldberg, Zarek C.; Che, Catherine; Handel, Benjamin R. - National Bureau of Economic Research - 2022

Despite their importance to the supply of prescription drugs, there has been limited research on pharmacy benefit managers (PBMs) and their vertical relationships to insurers and drug manufacturers. This paper provides an overview of the current state of research on this topic, motivates why...

Persistent link: https://www.econbiz.de/10013191054

Pricing and Reimbursement in U.S. Pharmaceutical Markets

Berndt, Ernst R. - 2010

branded pharmaceuticals. We then present a theoretical framework for the pricing of branded pharmaceuticals, without and then …

Persistent link: https://www.econbiz.de/10012462361

Intellectual Property & External Consumption Effects : Generalizations from Pharmaceutical Markets

Philipson, Tomas - 2003

There is a long-standing literature that recognizes that an efficient solution in correcting a consumption externality is through applying subsidies and taxes that line up private incentives with social ones. An equally long-standing literature tackles the appropriate methods of generating the...

Persistent link: https://www.econbiz.de/10012469100

The Objectives of the FDA's Office of Generic Drugs

Morton, Fiona Scott - 1997

I use variation in approval time for generic drugs to shed light on the objectives of the federal agency in charge of granting entry permission for these drugs (FDA). Applications belonging to firms later found to have engaged in fraud or corruption were approved nine months faster on average,...

Persistent link: https://www.econbiz.de/10012472670

1
2
3
4
5
6
7
8
9
10
Next
Last